The main outcome of the phase 3 THARROS trial will be to assess the efficacy of Breztri Aerosphere on reducing severe cardiopulmonary events in COPD patients who are at increased cardiopulmonary risk.

BREZTRI, already approved in over 80 countries for chronic obstructive pulmonary disease (COPD), may now offer hope to asthma sufferers. “We are excited by the positive results from the KALOS and ...

AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) has met the primary endpoints in two Phase III asthma ...

Breztri can cost $400 or more without insurance, but Medicare may cover inhaler drugs for COPD, including Breztri. That said, the specific coverage and costs vary based on your exact plan. Breztri ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled ...

(RTTNews) - AstraZeneca announced the initiation of THARROS, a Phase III trial to investigate the potential effect of triple-combination inhaled therapy BREZTRI AEROSPHERE on severe cardiopulmonary ...

On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials ...

THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD First patients dosed in ...